Search for: "IPR Pharmaceuticals, Inc."
Results 81 - 100
of 182
Sorted by Relevance
|
Sort by Date
23 Jan 2024, 2:32 am
Comment This decision is the first time the Court of Appeal has directly ruled on unjustified threats provisions in the context of Amazon’s IPR policy. [read post]
18 May 2018, 8:54 am
Praxair Distribution, Inc. v. [read post]
15 Oct 2019, 5:27 pm
Aoptex Inc. [read post]
16 Aug 2016, 5:15 pm
Teleflex Inc., 550 U.S.398 (2007), and cases from this court. [read post]
28 Sep 2016, 8:39 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
8 Apr 2024, 9:47 am
Vidal, with the pharmaceutical company challenging a PTAB IPR decision invalidating its patent. [read post]
8 Oct 2019, 9:44 am
LSI Corporation, No. 19-337 (state sovereign immunity against IPR challenge) Medtronic, Inc. v. [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
3 Jun 2016, 6:40 am
Momenta Pharmaceuticals, Inc., et al., No. 15-1402 (scope of 271(e) safe harbor) Exhaustion: Impression Products, Inc. v. [read post]
13 Mar 2024, 7:17 am
Collegium Pharmaceutical, Inc., No. 2022-1482 (Fed. [read post]
21 Sep 2018, 4:47 am
Regeneron Pharmaceuticals, Inc. v. [read post]
18 Oct 2007, 11:00 pm
Quite right, said the CFI, dismissing Intervideo's appeal - CFI decision in Case T-105/06 Intervideo v OHIM, (IPKat)EPO adds EPC post-grant data to PRS database (EPO), EU Patent Jurisdiction: Details of New Proposals From Portuguese EU Presidency (Blog@IPR::JUR), (IAM), Teva invalidates acid metabolite patents for terfenedine, (Teva Pharmaceutical Industries Ltd and another v Merrell Pharmaceuticals Inc, Aventis and Sepracor [2007] EWHC 2276 (Ch) ), (IPKat),… [read post]
14 Nov 2016, 9:16 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
18 Sep 2016, 6:03 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
5 Sep 2016, 6:46 pm
Fossil, Inc., et al, No. 16-202 (SCA Redux plus TM issue) Safe Harbor: Amphastar Pharmaceuticals, Inc., et al. v. [read post]
3 Oct 2018, 3:48 am
Samsung Electronics America, Inc. et al., No. 18-189 (PTAB judges as principal officers; retroactive CBM reviews) Regeneron Pharmaceuticals, Inc. v. [read post]
22 Aug 2015, 1:48 pm
His target has been pharmaceutical patents which he says have little value save for increasing the price of prescription drugs. [read post]
16 Nov 2007, 4:00 am
: (LawFont),BrazilBrazil pays the price for compulsory licensing: (IAM), (Generic Pharmaceuticals & IP), CanadaThe Chronicle reports that Honourable Mr. [read post]
3 May 2016, 1:42 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
